title: Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
abstract: Restrictive valvulopathy has been reported in association with dopamine agonist therapy in parkinsonian patients. The majority of reports have been related to pergolide, but anecdotal cases following treatment with bromocriptine or cabergoline have also been presented. It is presently unclear whether the potential induction of restrictive cardiac valvulopathy is a class effect of all dopamine agonists or if there is a differential risk between ergot and nonergot compounds. In this study, the frequency of a valvular regurgitation as assessed by routine transthoracic echocardiography was compared between 75 patients with Parkinson's disease (PD) treated with pergolide (n = 29), cabergoline (n = 13), pramipexole or ropinirole (n = 33), and 49 age-matched nonparkinsonian controls. The exposure to pergolide and cabergoline was associated with higher frequencies of valvular regurgitation grades 2 and 3 (31% and 47%) compared with age-matched controls (13%), while there was no increase of valvular regurgitation grades 2 and 3 in patients treated with nonergot compounds (10%). Evidence for restrictive valvulopathy was found in one patient treated with pergolide and cabergoline each. While this study shows similarly increased frequencies of valvular regurgitation in patients treated with the ergot agonists pergolide and cabergoline in comparison to both normal controls and patients treated with nonergot agonists, evidence for restrictive valvulopathy was only found in two cases. These results highlight the need for further prospective studies of the prevalence and underlying mechanisms of cardiac valvulopathy in PD patients treated with different dopamine agonists.
authors.affiliation: Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Peralta
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Wolf
authors.forename: Hannes
authors.initials: H
authors.lastname: Alber
authors.forename: Klaus
authors.initials: K
authors.lastname: Seppi
authors.forename: Silvana
authors.initials: S
authors.lastname: Müller
authors.forename: Sylvia
authors.initials: S
authors.lastname: Bösch
authors.forename: Gregor K
authors.initials: GK
authors.lastname: Wenning
authors.forename: Otmar
authors.initials: O
authors.lastname: Pachinger
authors.forename: Werner
authors.initials: W
authors.lastname: Poewe
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D004452:Echocardiography; D005260:Female; D006349:Heart Valve Diseases / Q000000981:diagnostic imaging* / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000000981:diagnostic imaging* / Q000188:drug therapy
chemical_list: D000978:Antiparkinson Agents